William J Dawson
CIK 1226139 · Chief Financial Officer · last filed 2026-03-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MGRC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
2411 STANWELL DRIVE
CONCORD, CA 94520
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MGRC | Director | 7,300 | $116.43 | $849.9K | -$5.20M | 45 | 2026-03-03 |
| Adamas Pharmaceuticals Inc (ADMS) Delisted | Chief Financial Officer | 14,284 | $8.22 | $117.4K | -$12.2K | 5 | 2017-03-22 |
| CERS | Chief Financial Officer | 156,825 | $2.35 | $369.3K | $108.7K | 8 | 2009-01-14 |
Recent Filings · Page 3 of 6
59 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-11-27 | MGRC | Sell (S) | −4,000 | -$191.3K | EDGAR |
| 2017-04-05 | MGRC | Exer (M) | +3,900 | $0 | EDGAR |
| 2017-03-22 | Adamas Pharmaceuticals Inc (ADMS) Delisted | Sell (S) | −716 | -$12.2K | EDGAR |
| 2017-03-06 | MGRC | Grant (A) | — | $0 | EDGAR |
| 2017-02-23 | Adamas Pharmaceuticals Inc (ADMS) Delisted | Grant (A) | +7,500 | $0 | EDGAR |
| 2016-06-15 | MGRC | Sell (S) | −5,000 | -$151.3K | EDGAR |
| 2016-03-08 | Adamas Pharmaceuticals Inc (ADMS) Delisted | Grant (A) | +7,500 | $102.5K | EDGAR |
| 2016-03-02 | MGRC | Grant (A) | — | $0 | EDGAR |
| 2015-08-12 | MGRC | Sell (S) | −3,000 | -$74.7K | EDGAR |
| 2015-04-03 | MGRC | Exer (M) | +2,800 | $92.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.